IndustryCompany release

Kazia files FY2026 20-F, reporting A$61.2M cash and early paxalisib breast cancer data

Kazia Therapeutics Ltd (KZIA) · Thu 19 Nov 2026

The Australian oncology company says cash, August offering proceeds and a Sovargen milestone should fund operations for at least 12 months, while paxalisib shows early activity in Stage IV triple-negative breast cancer.

Kazia Therapeutics filed its annual report on Form 20-F with the US Securities and Exchange Commission on 19 November 2026. The filing covers the fiscal year ended 30 June 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Kazia Therapeutics Ltd ↗

Article written by VigiEye from the official source (Kazia Therapeutics Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →